| Year |
Citation |
Score |
| 2024 |
Cheang MCU, Rimawi M, Johnston S, Jacobs SA, Bliss J, Pogue-Geile K, Kilburn L, Zhu Z, Schuster EF, Xiao H, Swaim L, Deng S, Lu DR, Gauthier E, Tursi J, ... Slamon DJ, et al. Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies. Npj Breast Cancer. 10: 54. PMID 38951507 DOI: 10.1038/s41523-024-00658-y |
0.318 |
|
| 2024 |
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Ruiz-Borrego M, Loi S, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. The New England Journal of Medicine. 390: 1080-1091. PMID 38507751 DOI: 10.1056/NEJMoa2305488 |
0.33 |
|
| 2023 |
Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS, Stroyakovskiy D, Xu B, Moroose RL, et al. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2- early breast cancer. Therapeutic Advances in Medical Oncology. 15: 17588359231178125. PMID 37275963 DOI: 10.1177/17588359231178125 |
0.321 |
|
| 2023 |
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 1501-1510. PMID 36881998 DOI: 10.1200/JCO.22.02510 |
0.313 |
|
| 2023 |
de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, Prat A, Lopez-Valverde V, Boulet T, Hurvitz SA. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Research : Bcr. 25: 2. PMID 36631725 DOI: 10.1186/s13058-022-01587-z |
0.309 |
|
| 2022 |
Wander SA, O'Brien N, Litchfield LM, O'Dea D, Morato Guimaraes C, Slamon DJ, Goel S. Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. The Oncologist. PMID 35917168 DOI: 10.1093/oncolo/oyac138 |
0.308 |
|
| 2022 |
O'Brien NA, Huang HKT, McDermott MSJ, Madrid AM, Luo T, Ayala R, Issakhanian S, Gong KW, Lu M, Zhang J, Slamon DJ. Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies. Molecular Cancer Therapeutics. OF1-OF11. PMID 35417017 DOI: 10.1158/1535-7163.MCT-21-0847 |
0.373 |
|
| 2021 |
Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching PA, Ejlertsen B, Yang EH, Glaspy JA, Slamon DJ. A careful reassessment of anthracycline use in curable breast cancer. Npj Breast Cancer. 7: 134. PMID 34625570 DOI: 10.1038/s41523-021-00342-5 |
0.315 |
|
| 2020 |
O'Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, ... Slamon DJ, et al. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Research : Bcr. 22: 89. PMID 32795346 DOI: 10.1186/S13058-020-01320-8 |
0.396 |
|
| 2020 |
Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, Shparyk YV, Thummala A, Voitko N, Bananis E, McRoy L, Wilner K, Huang X, Kim S, Slamon DJ, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Research and Treatment. PMID 32683565 DOI: 10.1007/S10549-020-05755-7 |
0.417 |
|
| 2020 |
Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, Leong HS, Chen S, Intermaggio MP, Gilks B, Nazeran TM, Volchek M, Elatre W, Bentley RC, ... ... Slamon DJ, et al. Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32554541 DOI: 10.1158/1078-0432.Ccr-20-0103 |
0.348 |
|
| 2020 |
Slamon DJ, Jerusalem G. Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply. The New England Journal of Medicine. 382: e85. PMID 32492319 DOI: 10.1056/NEJMc2004229 |
0.305 |
|
| 2020 |
Cummings AL, Kim DD, Rosen LS, Garon EB, Wainberg ZA, Slamon DJ, Goldman JW. A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps9084 |
0.336 |
|
| 2020 |
Yardley DA, Nusch A, Yap YS, Sonke GS, Bachelot T, Chan A, Neven P, Slamon DJ, Wheatley-Price P, Lteif A, Sondhi M, Rodriguez-Lorenc K, Gaur A, Chia SKL. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. Journal of Clinical Oncology. 38: 1054-1054. DOI: 10.1200/Jco.2020.38.15_Suppl.1054 |
0.362 |
|
| 2020 |
Okines AFC, Paplomata E, Wahl TA, Wright GLS, Sutherland S, Jakobsen E, Valdes F, Chan A, Clark AS, Conlin AK, Lustberg MB, Specht JM, Pluard TJ, Zhu X, Krop IE, ... ... Slamon DJ, et al. Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB). Journal of Clinical Oncology. 38: 1043-1043. DOI: 10.1200/Jco.2020.38.15_Suppl.1043 |
0.416 |
|
| 2020 |
Andre F, Su F, Solovieff N, Arteaga CL, Hortobagyi GN, Chia SKL, Neven P, Bardia A, Tripathy D, Lu Y, Wang Y, Rodriguez-Lorenc K, Taran T, Babbar N, Slamon DJ. Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. Journal of Clinical Oncology. 38: 1009-1009. DOI: 10.1200/Jco.2020.38.15_Suppl.1009 |
0.384 |
|
| 2020 |
Chia S, Su F, Neven P, Im S, Petrakova K, Bianchi GV, He W, Rodriguez-Lorenc K, Taran T, Babbar N, Slamon D. Abstract PD2-08: Gene expression analysis and association with treatment response in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer in the MONALEESA-3 study Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd2-08 |
0.448 |
|
| 2020 |
Caswell-Jin JL, McNamara KL, Dering J, Chen H, Dichmann R, Perez A, Patel R, Kotler E, Zoeller JJ, Brugge JS, Press MF, Slamon DJ, Curtis C, Hurvitz SA. Abstract P4-07-01: Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-07-01 |
0.443 |
|
| 2020 |
McDermott MS, Conklin DF, O'Brien NA, Chau K, Slamon DJ. Abstract P2-05-07: Pan-cancer analysis of PARP inhibition reveals a suite of biomarkers that correlate with PARP1/2 activity in breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-05-07 |
0.462 |
|
| 2020 |
Swain SM, Macharia H, Cortes J, Dang C, Gianni L, Hurvitz S, Jackisch C, Schneeweiss A, Slamon D, Valagussa P, Toit Yd, Heinzmann D, Knott A, Song C, Cortazar P. Abstract P1-18-01: Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-18-01 |
0.407 |
|
| 2020 |
Angelis CD, Fu X, Cataldo ML, Nardone A, Jansen VM, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Pereira R, Benelli M, Migliaccio I, Malorni L, Donaldson J, Selenica P, ... ... Slamon DJ, et al. Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs2-01 |
0.466 |
|
| 2020 |
McCann KE, Euw Ev, O'Brien N, Slamon D. Abstract 4124: The combination of PARP inhibitor talazoparib with low-dose temozolomide results in increased cell lethality in BRCA1/2 wild-type melanoma, small cell lung cancer, ovarian, and colon cancer cell lines and mouse xenografts via the formation of DNA double-strand breaks during S-phase Cancer Research. 80: 4124-4124. DOI: 10.1158/1538-7445.Am2020-4124 |
0.423 |
|
| 2019 |
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Val Bianchi G, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine. PMID 31826360 DOI: 10.1056/NEJMoa1911149 |
0.307 |
|
| 2019 |
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, ... ... Slamon D, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. The New England Journal of Medicine. PMID 31825569 DOI: 10.1056/NEJMoa1914609 |
0.335 |
|
| 2019 |
Hurvitz SA, Martín M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana SR, Brahmachary M, Ebert PJ, Hossain A, Liu J, ... ... Slamon DJ, et al. Potent cell cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, Phase 2 neoadjuvant study in HR+/HER2- breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31615937 DOI: 10.1158/1078-0432.CCR-19-1425 |
0.302 |
|
| 2019 |
Finn RS, Liu Y, Zhu Z, Martín M, Rugo HS, Diéras V, Im SA, Gelmon KA, Harbeck N, Lu DR, Gauthier E, Huang Bartlett C, Slamon DJ. Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31527167 DOI: 10.1158/1078-0432.Ccr-19-0751 |
0.33 |
|
| 2019 |
Zoeller JJ, Vagodny A, Taneja K, Tan BY, O'Brien N, Slamon DJ, Sampath D, Leverson JD, Bronson RT, Dillon DA, Brugge JS. Neutralization of BCL-2/XL enhances the cytotoxicity of T-DM1 in vivo. Molecular Cancer Therapeutics. PMID 30962322 DOI: 10.1158/1535-7163.Mct-18-0743 |
0.308 |
|
| 2019 |
Slamon DJ, Fasching PA, Patel R, Verma S, Hurvitz SA, Chia SKL, Crown J, Martin M, Barrios CH, Spera G, Lopez C, Hor I, Pelov D, Hughes G, Nawinne M, et al. NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps597 |
0.395 |
|
| 2019 |
Hurvitz SA, Martin M, Jung KH, Huang C, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau J, Beckmann MW, Afenjar K, Spera G, Valverde VL, Song C, ... ... Slamon DJ, et al. Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study. Journal of Clinical Oncology. 37: 500-500. DOI: 10.1200/Jco.2019.37.15_Suppl.500 |
0.357 |
|
| 2019 |
Chan A, Spera G, Machado A, Fung H, Bee V, Fresco R, Slamon D. Abstract PD3-12: Central nervous system as first site of relapse in patients with HER2 positive early breast cancer treated in the BCIRG-006 trial Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd3-12 |
0.398 |
|
| 2019 |
Zoeller JJ, Hurvitz SA, Press MF, Selfors LM, Dering J, Slamon DJ, Brugge JS. Abstract 2978: Clinical evaluation of lapatinib induced BCL-2 adaptive responses Cancer Research. 79: 2978-2978. DOI: 10.1158/1538-7445.Sabcs18-2978 |
0.374 |
|
| 2019 |
O'Brien NA, McDermott MS, Conklin DF, Gaither A, Luo T, Ayala R, Salgar S, DiTomaso E, Babbar N, Su F, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ. Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models Cancer Research. 79: 3825-3825. DOI: 10.1158/1538-7445.Am2019-3825 |
0.454 |
|
| 2018 |
Press MF, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, ... ... Slamon DJ, et al. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. Jama Oncology. PMID 30520947 DOI: 10.1001/Jamaoncol.2018.6012 |
0.332 |
|
| 2018 |
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine. PMID 30345905 DOI: 10.1056/Nejmoa1810527 |
0.317 |
|
| 2018 |
Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, Masuda N, Verma S, Loi S, Colleoni M, Theall KP, Huang X, Liu Y, Bartlett CH. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. European Journal of Cancer (Oxford, England : 1990). 104: 21-31. PMID 30308388 DOI: 10.1016/J.Ejca.2018.08.011 |
0.301 |
|
| 2018 |
Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, ... Slamon D, et al. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. Bmc Cancer. 18: 965. PMID 30305055 DOI: 10.1186/s12885-018-4852-1 |
0.339 |
|
| 2018 |
O'Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, Mc Nulty A, Marchal C, Kalous O, von Euw E, Hurvitz S, Mockbee C, Slamon DJ. Preclinical activity of abemaciclib alone or in combination with anti-mitotic and targeted therapies in breast cancer. Molecular Cancer Therapeutics. PMID 29483214 DOI: 10.1158/1535-7163.Mct-17-0290 |
0.377 |
|
| 2018 |
Du Q, Yu R, Wang H, Yan D, Yuan Q, Ma Y, Slamon D, Hou D, Wang H, Wang Q. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer. The Clinical Respiratory Journal. PMID 29356386 DOI: 10.1111/Crj.12769 |
0.342 |
|
| 2018 |
Finn RS, Cristofanilli M, Ettl J, Gelmon KA, Verma S, Colleoni M, Giorgetti C, Gauthier ER, Liu Y, Lu D(, Bartlett CH, Slamon DJ, Turner NC, Rugo HS. Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3. Journal of Clinical Oncology. 36: 1023-1023. DOI: 10.1200/Jco.2018.36.15_Suppl.1023 |
0.332 |
|
| 2017 |
Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, ... ... Slamon D, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Oncology. PMID 29175149 DOI: 10.1016/S1470-2045(17)30716-7 |
0.32 |
|
| 2017 |
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 169: 361. PMID 28388418 DOI: 10.1016/J.Cell.2017.03.036 |
0.304 |
|
| 2017 |
Fejzo MS, Anderson L, Chen HW, Guandique E, Kalous O, Conklin D, Slamon DJ. Proteasome Ubiquitin Receptor PSMD4 is an Amplification Target in Breast Cancer and May Predict Sensitivity to PARPi. Genes, Chromosomes & Cancer. PMID 28316110 DOI: 10.1002/Gcc.22459 |
0.357 |
|
| 2017 |
Jiang J, Zhao H, Shu W, Tian J, Huang Y, Song Y, Wang R, Li E, Slamon D, Hou D, Du X, Zhang L, Chen Y, Wang Q. An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cells. Scientific Reports. 7: 42612. PMID 28198402 DOI: 10.1038/Srep42612 |
0.321 |
|
| 2017 |
Drakaki A, Koutsioumpa M, O'Brien NA, Vorvis C, Iliopoulos D, Slamon DJ. A chemically-modified miR-21 inhibitor (ADM-21) as a novel potential therapy in bladder cancer. Journal of Clinical Oncology. 35: 335-335. DOI: 10.1200/Jco.2017.35.6_Suppl.335 |
0.346 |
|
| 2017 |
Finn RS, Crown J, Lang I, Boer K, Bondarenko I, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk YV, Thummala A, Voytko NL, Fowst C, Huang X, ... ... Slamon DJ, et al. Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). Journal of Clinical Oncology. 35: 1001-1001. DOI: 10.1200/Jco.2017.35.15_Suppl.1001 |
0.362 |
|
| 2017 |
Anders C, Murthy R, Hamilton E, Borges V, Cameron D, Carey L, Müller V, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pivot X, Pegram M, Slamon D, et al. Abstract CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct055 |
0.37 |
|
| 2017 |
O'Brien NA, Conklin D, Luo T, Ayala R, Issakhanian S, Kalous O, Euw EV, Hurvitz SA, DiTomaso E, Su F, Linnartz R, Scherer S, Hirawat S, Slamon DJ. Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy Cancer Research. 77: 4150-4150. DOI: 10.1158/1538-7445.Am2017-4150 |
0.42 |
|
| 2016 |
Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, King K, Koski S, Mulder K, Hiller JP, Scarfe A, et al. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. Jama Oncology. PMID 27737436 DOI: 10.1001/Jamaoncol.2016.3358 |
0.348 |
|
| 2016 |
Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, Pinter T, Boer K, Patel R, Randolph S, Kim ST, Huang X, Schnell P, Nadanaciva S, Bartlett CH, ... Slamon DJ, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Research : Bcr. 18: 67. PMID 27349747 DOI: 10.1186/s13058-016-0721-5 |
0.322 |
|
| 2016 |
André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, ... Slamon D, et al. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27091708 DOI: 10.1200/JCO.2015.63.9161 |
0.336 |
|
| 2016 |
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 164: 1073. PMID 27064190 DOI: 10.1016/J.Cell.2015.10.020 |
0.304 |
|
| 2016 |
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, ... ... Slamon D, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. Oncology. PMID 26947331 DOI: 10.1016/S1470-2045(15)00613-0 |
0.348 |
|
| 2016 |
Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Research : Bcr. 18: 17. PMID 26857361 DOI: 10.1186/s13058-015-0661-5 |
0.338 |
|
| 2016 |
Konecny GE, Hendrickson AEW, Jatoi A, Burton JK, Paroly J, Glaspy JA, Dowdy SC, Slamon DJ. A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer. Journal of Clinical Oncology. 34: 5557-5557. DOI: 10.1200/Jco.2016.34.15_Suppl.5557 |
0.357 |
|
| 2016 |
Press MF, Sauter G, Buyse ME, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee-Munteanu V, Ma Y, ... ... Slamon DJ, et al. HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials. Journal of Clinical Oncology. 34: 515-515. DOI: 10.1200/Jco.2016.34.15_Suppl.515 |
0.403 |
|
| 2016 |
Finn RS, Martin M, Rugo HS, Jones SE, Im S, Gelmon KA, Harbeck N, Lipatov ON, Walshe JM, Moulder SL, Gauthier ER, Lu D(, Randolph S, Diéras V, Slamon DJ. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). Journal of Clinical Oncology. 34: 507-507. DOI: 10.1200/Jco.2016.34.15_Suppl.507 |
0.347 |
|
| 2016 |
Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang C, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Afenjar K, Fresco R, Helms H, Xu J, Lin YG, ... ... Slamon DJ, et al. Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). Journal of Clinical Oncology. 34: 500-500. DOI: 10.1200/Jco.2016.34.15_Suppl.500 |
0.4 |
|
| 2016 |
Bedard PL, Cescon DW, Fletcher G, Denny T, Brokx R, Sampson P, Bray MR, Slamon DJ, Mak TW, Wainberg ZA. Abstract CT066: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct066 |
0.361 |
|
| 2016 |
Kalous O, Conklin D, Manivong K, Wayne W, Hanestad K, Canon J, Loberg R, Friberg G, Gamelin E, Vogl FD, Juan G, Coxon A, Slamon D, Finn R, Payton M. Abstract 3008: Preclinical characterization of AMG 900, a pan-aurora kinase inhibitor, alone and in combination with taxanes in ovarian cancer Cancer Research. 76: 3008-3008. DOI: 10.1158/1538-7445.Am2016-3008 |
0.455 |
|
| 2016 |
O’Brien NA, Conklin D, Luo T, Kalous O, Euw Ev, Hurvitz SA, Beckmann RP, Mockbee C, Slamon DJ. Abstract 2828: Preclinical activity of abemaciclib as a single agent or in combination with anti-mitotic or targeted therapies for breast cancer Cancer Research. 76: 2828-2828. DOI: 10.1158/1538-7445.Am2016-2828 |
0.475 |
|
| 2016 |
Press MF, Xie B, Davenport S, Zhou Y, O’Brien N, Palazzolo M, Mak T, Brugge J, Slamon DJ. Abstract 2736: Regulation of cytokinesis by polo-like kinase 4 Cancer Research. 76: 2736-2736. DOI: 10.1158/1538-7445.Am2016-2736 |
0.395 |
|
| 2016 |
Hurvitz SA, Euw Ev, O’Brien N, Conklin D, Hu C, Zhuo J, Zhao A, Calzone F, Chen H, Dering J, Geles K, Sapra P, Slamon DJ. Abstract 1206: Preclinical evaluation of targeting Notch-3 in breast cancer Cancer Research. 76: 1206-1206. DOI: 10.1158/1538-7445.Am2016-1206 |
0.47 |
|
| 2016 |
DRAKAKI A, O'BRIEN N, VORVIS C, ILIOPOULOS D, SLAMON D. MP88-11 THERAPEUTIC EFFECTS OF A MICRORNA-21 CHEMICAL INHIBITOR ON BLADDER CANCER PRECLINICAL MODELS Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2429 |
0.337 |
|
| 2015 |
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Buhu S, Slamon DJ, Wolchok JD, Pardoll DM, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 162: 974-86. PMID 26317466 DOI: 10.1016/J.Cell.2015.07.011 |
0.382 |
|
| 2015 |
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, ... ... Slamon D, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. The Lancet. Oncology. 16: 816-29. PMID 26092818 DOI: 10.1016/S1470-2045(15)00051-0 |
0.334 |
|
| 2015 |
Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Research and Treatment. 149: 669-80. PMID 25663547 DOI: 10.1007/S10549-015-3282-X |
0.377 |
|
| 2015 |
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, ... ... Slamon DJ, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. The Lancet. Oncology. 16: 25-35. PMID 25524798 DOI: 10.1016/S1470-2045(14)71159-3 |
0.332 |
|
| 2015 |
Drew BG, Hamidi H, Zhou Z, Villanueva CJ, Krum SA, Calkin AC, Parks BW, Ribas V, Kalajian NY, Phun J, Daraei P, Christofk HR, Hewitt SC, Korach KS, Tontonoz P, ... ... Slamon DJ, et al. Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression. The Journal of Biological Chemistry. 290: 5566-81. PMID 25468909 DOI: 10.1074/Jbc.M114.606459 |
0.389 |
|
| 2015 |
Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, ... ... Slamon DJ, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 304-11. PMID 25452441 DOI: 10.1200/Jco.2014.57.1414 |
0.306 |
|
| 2015 |
Bilchik AJ, Wainberg ZA, Nissan A, Slamon DJ, Protic M, Avital I, Chen HW, Chen D, Sim M, Elashoff D, Stojadinovic A. Value of primary tumor gene signatures in colon cancer when national quality standards are adhered to: preliminary results of an international prospective multicenter trial. Annals of Surgical Oncology. 22: 535-42. PMID 25190115 DOI: 10.1245/S10434-014-4013-Y |
0.349 |
|
| 2015 |
Finn RS, Crown J, Ettl J, Pinter T, Thummala A, Shparyk YV, Patel R, Randolph S, Kim S, Huang X, Jiang Y, Bartlett CH, Slamon DJ. Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18. Journal of Clinical Oncology. 33: 575-575. DOI: 10.1200/Jco.2015.33.15_Suppl.575 |
0.349 |
|
| 2015 |
Finn RS, Crown J, Lang I, Kulyk SO, Schmidt M, Patel R, Thummala A, Bondarenko I, Randolph S, Kim S, Huang X, Donnelly E, Bartlett CH, Slamon DJ. The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/ HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study. Journal of Clinical Oncology. 33: 572-572. DOI: 10.1200/Jco.2015.33.15_Suppl.572 |
0.311 |
|
| 2015 |
Crown J, Finn RS, Ettl J, Boer K, Patel R, Thummala A, Randolph S, Kim S, Huang X, Nadanaciva S, Schnell P, Bartlett CH, Slamon DJ. Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial. Journal of Clinical Oncology. 33: 571-571. DOI: 10.1200/Jco.2015.33.15_Suppl.571 |
0.409 |
|
| 2015 |
Slamon DJ, Crown J, Lang I, Kulyk SO, Schmidt M, Patel R, Thummala A, Voytko NL, Randolph S, Kim S, Huang X, Bartlett CH, Schnell P, Finn RS. Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18). Journal of Clinical Oncology. 33: 570-570. DOI: 10.1200/Jco.2015.33.15_Suppl.570 |
0.351 |
|
| 2015 |
Slamon DJ, Hurvitz SA, Chen D, Andre F, Tseng L, Jerusalem GHM, Wilks S, O'Regan R, Isaacs C, Toi M, Burris HA, He W, Riester M, Robinson D, Taran T, et al. Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3. Journal of Clinical Oncology. 33: 512-512. DOI: 10.1200/Jco.2015.33.15_Suppl.512 |
0.437 |
|
| 2015 |
Mullooly M, Conklin D, McGowan PM, O'Brien NA, O'Donovan N, Slamon DJ, Crown J, Finn RS, Duffy MJ. Neratinib to inhibit the growth of triple-negative breast cancer cells. Journal of Clinical Oncology. 33: 1099-1099. DOI: 10.1200/Jco.2015.33.15_Suppl.1099 |
0.476 |
|
| 2015 |
Mead M, Euw EV, Conklin D, Powell B, Manivong K, Do E, Slamon DJ, Larson S. Efficacy and Mechanism of Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies Blood. 126: 3702-3702. DOI: 10.1182/Blood.V126.23.3702.3702 |
0.354 |
|
| 2015 |
Bell T, Crown JP, Lang I, Bhattacharyya H, Zanotti G, Randolph S, Kim S, Huang X, Bartlett CH, Finn R, Slamon D. Abstract P5-19-19: Impact of adding palbociclib to letrozole on pain severity and pain interference with various activities of daily life in patients with ER+, HER2- metastatic breast cancer as first line treatment Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-19-19 |
0.336 |
|
| 2015 |
O'Brien NA, Conklin D, Ching M, Tong L, Ayala R, Issakhanian S, Hurvitz SA, Tomaso Ed, Linnartz R, Finn RS, Hirawat S, Slamon DJ. Abstract P5-05-04: Acquired resistance to everolimus occurs independently of mTORC1 inhibition in preclinical in vivo models of ER+ breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-05-04 |
0.441 |
|
| 2015 |
Wong DJ, Shin DD, Ratikan J, Chalukya M, Manivong K, Post L, Schaue D, Finn RS, Shen Y(, McBride W, Slamon DJ. Abstract 1795: Potent anti-tumor activity of talazoparib (BMN673) in combination with radiation for squamous cell carcinoma of the head and neck Cancer Research. 75: 1795-1795. DOI: 10.1158/1538-7445.Am2015-1795 |
0.339 |
|
| 2014 |
Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, Linnartz R, Zubel A, Slamon DJ, Finn RS. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. British Journal of Cancer. 111: 1788-801. PMID 25167228 DOI: 10.1038/Bjc.2014.475 |
0.366 |
|
| 2014 |
Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. The Journal of Clinical Investigation. 124: 2611-25. PMID 24762435 DOI: 10.1172/Jci69815 |
0.419 |
|
| 2014 |
Liu B, Tahk S, Yee KM, Yang R, Yang Y, Mackie R, Hsu C, Chernishof V, O'Brien N, Jin Y, Fan G, Lane TF, Rao J, Slamon D, Shuai K. PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing. Plos One. 9: e89464. PMID 24586797 DOI: 10.1371/Journal.Pone.0089464 |
0.3 |
|
| 2014 |
Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, Jones PA, Slamon DJ, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 5: 587-98. PMID 24583822 DOI: 10.18632/Oncotarget.1782 |
0.424 |
|
| 2014 |
Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, Patel C, von Euw E, Black A, Michelakis ED, Dubinett SM, ... Slamon DJ, et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 140: 443-52. PMID 24442098 DOI: 10.1007/S00432-014-1583-9 |
0.314 |
|
| 2014 |
Konecny GE, Haluska P, Janicke F, Sehouli J, Beckmann MW, Feisel G, Pölcher M, Roman L, Rody A, Karlan B, Ray-Coquard IL, Provencher DM, Ben-Baruch N, Cottu PH, Chen H, ... ... Slamon DJ, et al. A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial. Journal of Clinical Oncology. 32: 5529-5529. DOI: 10.1200/Jco.2014.32.15_Suppl.5529 |
0.386 |
|
| 2014 |
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk YV, Thummala AR, Voytko NL, Huang X, Kim ST, ... ... Slamon DJ, et al. Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18) Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct101 |
0.399 |
|
| 2014 |
Wong DJ, Garon EB, Silveira DD, Kamranpour N, Pitts S, Chalukya M, Hamidi H, Dubinett S, Linnartz R, Finn RS, Slamon DJ. Abstract 743: Potent anti-tumor activity of the MEK1/2 inhibitor MEK162 in human non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN) cell lines Cancer Research. 74: 743-743. DOI: 10.1158/1538-7445.Am2014-743 |
0.421 |
|
| 2014 |
O'Brien NA, Tomaso ED, Ayala R, Tong L, Issakhanian S, Linnartz R, Finn RS, Hirawat S, Slamon DJ. Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer Cancer Research. 74: 4756-4756. DOI: 10.1158/1538-7445.Am2014-4756 |
0.44 |
|
| 2014 |
Euw EMv, Conklin D, Rong H, Gong K, Finn RS, Slamon DJ. Abstract 1321: Identification of markers of sensitivity and resistance to palbociclib (PD0332991) in melanoma Cancer Research. 74: 1321-1321. DOI: 10.1158/1538-7445.Am2014-1321 |
0.401 |
|
| 2014 |
Goldman JW, Garon EB, Conklin D, Wong DJL, Wolf B, Silveira DD, Kamranpour N, Pitts S, Finn RS, Slamon DJ. 498 CDK4/6 inhibitor (LY2835219) exhibits potent anti-tumor activity in human lung cancer cell lines with intact retinoblastoma European Journal of Cancer. 50: 162. DOI: 10.1016/S0959-8049(14)70624-0 |
0.389 |
|
| 2013 |
Bang YJ, Qin S, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero AF, Salman P, Li J, Protsenko S, Buyse ME, Afenjar K, Kaneko T, ... ... Slamon DJ, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: LBA4001. PMID 28136050 DOI: 10.1200/Jco.2013.31.18_Suppl.Lba4001 |
0.371 |
|
| 2013 |
Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Research and Treatment. 141: 397-408. PMID 24091768 DOI: 10.1007/S10549-013-2702-Z |
0.339 |
|
| 2013 |
Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, ... ... Slamon DJ, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Molecular Cancer Therapeutics. 12: 1002-15. PMID 23729402 DOI: 10.1158/1535-7163.Mct-12-0813 |
0.333 |
|
| 2013 |
Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, ... ... Slamon DJ, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Molecular Cancer Therapeutics. 12: 632-42. PMID 23443805 DOI: 10.1158/1535-7163.MCT-12-0999 |
0.33 |
|
| 2013 |
Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Molecular Cancer Therapeutics. 12: 509-19. PMID 23395886 DOI: 10.1158/1535-7163.Mct-12-0507 |
0.345 |
|
| 2013 |
Fejzo MS, Anderson L, von Euw EM, Kalous O, Avliyakulov NK, Haykinson MJ, Konecny GE, Finn RS, Slamon DJ. Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer. International Journal of Molecular Sciences. 14: 3094-109. PMID 23377018 DOI: 10.3390/ijms14023094 |
0.33 |
|
| 2013 |
Johnston SR, Gómez H, Stemmer SM, Richie M, Durante M, Pandite L, Goodman V, Slamon D. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Research and Treatment. 137: 755-66. PMID 23283526 DOI: 10.1007/s10549-012-2399-4 |
0.31 |
|
| 2013 |
Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene. 32: 554-63. PMID 22391567 DOI: 10.1038/Onc.2012.62 |
0.472 |
|
| 2013 |
Finn RS, Dieras V, Gelmon KA, Harbeck N, Jones SE, Koehler M, Martin M, Rugo HS, Im S, Toi M, Gauthier ER, Huang X, Randolph S, Slamon DJ. A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(–) breast cancer who have not received any prior systemic anticancer treatment for advanced disease. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps652 |
0.368 |
|
| 2013 |
Michiels S, Pugliano L, Grun D, Barinoff J, Cameron DA, Cobleigh MA, Leo AD, Johnston SRD, Gasparini G, Kaufman B, Marty ME, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon DJ, et al. Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis. Journal of Clinical Oncology. 31: 610-610. DOI: 10.1200/Jco.2013.31.15_Suppl.610 |
0.374 |
|
| 2013 |
Ray-Coquard I, Haluska P, O'Reilly S, Cottu PH, Elit L, Provencher DM, Beckmann MW, Bosserman LD, Jacod S, Houe V, Loberg RD, Glaspy JA, Karlan B, Slamon DJ, Konecny GE. A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology. 31: 5515-5515. DOI: 10.1200/Jco.2013.31.15_Suppl.5515 |
0.367 |
|
| 2013 |
Konecny GE, Wang C, Winterhoff B, Dering J, Ginther C, Chen H, Hamidi H, Podratz KC, Cliby W, Dowdy SC, Haluska P, Hartmann LC, Kalli K, Goode EL, Slamon DJ. Prognostic relevance of gene signatures in high-grade serous ovarian carcinoma. Journal of Clinical Oncology. 31: 5510-5510. DOI: 10.1200/Jco.2013.31.15_Suppl.5510 |
0.387 |
|
| 2013 |
Mullooly M, O'Brien NA, Conklin D, Finn RS, Slamon DJ, Crown J, O'Donovan N, McGowan PM, Duffy MJ. Preclinical studies with neratinib in triple-negative breast cancer. Journal of Clinical Oncology. 31: 1054-1054. DOI: 10.1200/Jco.2013.31.15_Suppl.1054 |
0.463 |
|
| 2013 |
McDermott M, Anderson L, Shields L, O'Brien N, Prendergast A, Kennedy S, Gallagher W, Zagozdzon R, Byrne A, Crown J, Slamon D, O'Donovan N. Abstract 5634: Increased co-amplification of HER2 and STARD3 in a cell line model of acquired lapatinib resistance. Cancer Research. 73: 5634-5634. DOI: 10.1158/1538-7445.Am2013-5634 |
0.349 |
|
| 2013 |
Garon EB, Siegfried JM, Dubinett SM, Elashoff RM, Park DJ, Parikh RJ, Patel R, Hu EH, Reckamp KL, Adams B, Martinez D, Wang H, Kabbinavar F, Dacic S, Brennan M, ... ... Slamon DJ, et al. Abstract 4664: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). Cancer Research. 73: 4664-4664. DOI: 10.1158/1538-7445.Am2013-4664 |
0.351 |
|
| 2013 |
Euw EMV, Rong H, O'Brien N, Conklin D, Konkankit V, Gong K, Zubel A, Linnartz R, Finn R, Chmielowski B, Slamon D. Abstract 2437: MEK162 (ARRY 438162), a MEK1/2 inhibitor, has activity in melanoma cells independent of BRAF and NRAS mutation status. Cancer Research. 73: 2437-2437. DOI: 10.1158/1538-7445.Am2013-2437 |
0.394 |
|
| 2013 |
Euw EMV, Pace E, Covarrubias K, Jairam A, Chai D, Konkankit V, Gong K, Johnson B, Schoeberl B, Lugovskoy A, Richard F, Slamon D. Abstract 2077A: MM141, a novel bispecific antibody co-inhibitor of IGF-1R and ErbB3, inhibits the proliferation of melanoma cells. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-2077A |
0.402 |
|
| 2013 |
Shin DD, Ratikan J, Manivong K, Chalukya M, Post L, Shen Y(, McBride W, Schaue D, Slamon DJ, Finn RS. Abstract 1595: The poly(ADP-ribose) polymerase inhibitor BMN 673 has single agent activity and augments cytotoxicity of radiation in human head and neck tumor cell linein vitro: a novel strategy for radiosensitization in head and neck cancer. Cancer Research. 73: 1595-1595. DOI: 10.1158/1538-7445.Am2013-1595 |
0.391 |
|
| 2012 |
Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Molecular Cancer Research : McR. 10: 1597-606. PMID 23071104 DOI: 10.1158/1541-7786.Mcr-12-0155-T |
0.377 |
|
| 2012 |
Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Molecular Cancer Therapeutics. 11: 1978-87. PMID 22761403 DOI: 10.1158/1535-7163.Mct-11-0730 |
0.369 |
|
| 2012 |
Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, ... ... Slamon DJ, et al. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3478-86. PMID 22504044 DOI: 10.1158/1078-0432.Ccr-11-2294 |
0.352 |
|
| 2012 |
Euw EMV, Dering J, Anderson L, Ginther C, Cheng H, Gong K, Konkankit VV, Finn RS, Slamon DJ. Molecular profiling and comparative genomic hybridization analysis in human melanoma cell lines and identification of BRAF amplification in a PLX4032 acquired resistance cell line. Journal of Clinical Oncology. 30: 8592-8592. DOI: 10.1200/Jco.2012.30.15_Suppl.8592 |
0.347 |
|
| 2012 |
Essner R, Gong KW, Chmielowski B, Finn R, Tap WD, Slamon D. Abstract 4570: Functional analysis of gene expression profiling of primary and metastatic melanoma: Possible implications from BRAF mutant and wild-type cell lines Cancer Research. 72: 4570-4570. DOI: 10.1158/1538-7445.Am2012-4570 |
0.366 |
|
| 2012 |
Finn RS, Aleshin A, Zhao D, Anderson L, Ginther C, Dering J, Shi M, Porta DG, Busuttil RW, Slamon DJ. Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398in vitro Cancer Research. 72: 3858-3858. DOI: 10.1158/1538-7445.Am2012-3858 |
0.356 |
|
| 2012 |
Wainberg ZA, Rogers A, O'Brien N, Anghel A, Desai A, Kalous O, Conklin D, Akimov M, Finn RS, Slamon DJ. Abstract 3668: Inhibition of HSP90 with NVP-AUY922 induces a synergistic effect in HER2-amplified, trastuzumab-resistant breast and gastric cancer Cancer Research. 72: 3668-3668. DOI: 10.1158/1538-7445.Am2012-3668 |
0.445 |
|
| 2012 |
Hurvitz SA, Hegde P, Bosserman L, Allison MA, Thirlwell M, Yeh R, Fu L, Schmidt M, Leyland-Jones B, Quan E, Molthrop D, Barstis J, Park D, Keane M, Upadhyaya G, ... ... Slamon DJ, et al. Abstract 1385: Molecular changes in breast tumors following bevacizumab-based treatment: Final analysis of a randomized neoadjuvant study of bevacizumab or placebo, followed by chemotherapy with or without bevacizumab, in patients with stage II or III breast cancer Cancer Research. 72: 1385-1385. DOI: 10.1158/1538-7445.Am2012-1385 |
0.409 |
|
| 2012 |
Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Abstract B31: Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab resistant HER2-overexpressing breast cancer cells. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-B31 |
0.394 |
|
| 2012 |
Mullooly M, O'Brien N, Finn RS, Slamon DJ, Crown J, McGowan PM, Duffy MJ. 558 Dual Targeting of ADAM10 and ADAM17 as a Novel Therapy for Breast Cancer European Journal of Cancer. 48: 171. DOI: 10.1016/S0959-8049(12)72355-9 |
0.403 |
|
| 2012 |
McDermott MS, Browne BC, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. 145 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer European Journal of Cancer. 48: 45. DOI: 10.1016/S0959-8049(12)71943-3 |
0.398 |
|
| 2011 |
Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, ... ... Slamon DJ, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 149-56. PMID 21115860 DOI: 10.1200/JCO.2010.28.6450 |
0.338 |
|
| 2011 |
Wu Y, Mosher N, Kim J, Chung S, Ginther C, Slamon D, Vadgama JV. Abstract 710: Gene expression profile of the Wnt signaling pathway in trastuzumab resistant breast cancer cells Cancer Research. 71: 710-710. DOI: 10.1158/1538-7445.Am2011-710 |
0.414 |
|
| 2011 |
Davidowitz R, Iwanicki M, Selfors L, Konecny G, Dering J, Slamon D, Brugge J. Abstract 4751: Identification of mechanism involved in mesothelial clearance by ovarian tumor spheroids Cancer Research. 71: 4751-4751. DOI: 10.1158/1538-7445.Am2011-4751 |
0.413 |
|
| 2011 |
Konecny GE, Winterhoff B, Guorong EY, Qi J, Le J, Shi M, Dugan M, Linnartz R, Finn RS, Slamon DJ. Abstract 3589: Dovitinib (TKI258), a multikinase inhibitor of FGFR, PDGFR, and VEGFR tyrosine kinases, induces growth inhibition in endometrial carcinoma cells Cancer Research. 71: 3589-3589. DOI: 10.1158/1538-7445.Am2011-3589 |
0.426 |
|
| 2011 |
Venkatesan N, Issakhanian SP, Ginther CG, Slamon DJ, Srivatsan ES, Veena MS. Abstract 2201: Involvement of somatic mutations in silencing cystatin E/M tumor suppressor gene in breast cancer Cancer Research. 71: 2201-2201. DOI: 10.1158/1538-7445.Am2011-2201 |
0.453 |
|
| 2011 |
McDermott M, Anderson L, O'Brien N, Crown J, Slamon DJ, O'Donovan N. 1049 POSTER Increased Amplification of HER2 in a Cell Line Model of Acquired Lapatinib Resistance European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)70692-X |
0.307 |
|
| 2011 |
Winterhoff B, Haluska P, Kalli K, Cliby W, Gostout B, Oberg A, Maurer M, Hartmann L, Slamon D, Konecny G. Insulin-like growth factor receptor 1 pathway signature correlates with adverse clinical outcome in ovarian cancer Gynecologic Oncology. 120. DOI: 10.1016/J.Ygyno.2010.12.172 |
0.304 |
|
| 2010 |
Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Molecular Cancer Therapeutics. 9: 1985-94. PMID 20587667 DOI: 10.1158/1535-7163.Mct-10-0037 |
0.38 |
|
| 2010 |
Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Research. 70: 5475-85. PMID 20551062 DOI: 10.1158/0008-5472.CAN-10-0176 |
0.364 |
|
| 2010 |
Britten CD, Chow L, Conklin D, Kalous O, Desai A, Ginther C, Dering J, Christensen J, Milham R, Slamon DJ, Finn RS. Abstract LB-70:In vitroanti-cancer activity of PF-04691502, a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) in a panel of human breast cancer cell lines Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-70 |
0.485 |
|
| 2010 |
O'Brien NA, Wang Y, Chow L, Wilcox K, Browne B, Crown J, Arboleda J, Ginther C, Duffy MJ, O'Donovan N, Slamon DJ. Abstract 613: Increased PI3K/AKT activity, which confers resistance to trastuzumab, can be overcome by lapatinib Cancer Research. 70: 613-613. DOI: 10.1158/1538-7445.Am10-613 |
0.39 |
|
| 2010 |
Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. Abstract 612: FOXO1A is a target for HER2 overexpressing breast tumors Cancer Research. 70: 612-612. DOI: 10.1158/1538-7445.Am10-612 |
0.474 |
|
| 2010 |
Atefi MS, Zheng C, Atefi Z, Slamon DJ. Abstract 4602: Effect of estrogen receptor antagonistic drugs on expression and regulation of fatty acid synthase (FAS) in ER+ breast cancer cell lines Cancer Research. 70: 4602-4602. DOI: 10.1158/1538-7445.Am10-4602 |
0.406 |
|
| 2010 |
Zhu M, Saxton RE, Ramos L, Chang DD, Karlan BY, Gasson JC, Slamon DJ. Abstract 4407: Neutralizing monoclonal antibody to periostin (PN) inhibits ovarian tumor metastatic growth in animal models Cancer Research. 70: 4407-4407. DOI: 10.1158/1538-7445.Am10-4407 |
0.409 |
|
| 2010 |
McDermott M, Browne B, Crown J, O'Brien N, Slamon D, Henry M, Meleady P, Clynes M, Dowling P, O'Donovan N. Abstract 3633: eEF2 in acquired lapatinib resistance in HER2 positive breast cancer cells Cancer Research. 70: 3633-3633. DOI: 10.1158/1538-7445.Am10-3633 |
0.452 |
|
| 2010 |
Kolarova T, Winterhoff B, Qi J, Manivong K, Chalukya M, Kalli K, Hartmann L, Cliby W, Slamon D, Konecny G. Abstract 25: PD 0332991, a selective CDK 4/6 inhibitor, preferentially inhibits growth of ovarian cancer cells with high Rb and low p16 (CDKN2A) expression Cancer Research. 70: 25-25. DOI: 10.1158/1538-7445.Am10-25 |
0.385 |
|
| 2010 |
Wu Y, Sarkissyan M, Elshimali Y, Mohamed H, Clayton S, Slamon D, Koeffler PH, Vadgama JV. Abstract A97: Loss of function for FOXO1A contributes to poor outcome in African American and Latina women with breast cancer Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A97 |
0.461 |
|
| 2010 |
Vadgama JV, Wu Y, Sarkissyan M, Elshimali Y, Mohamed H, Clayton S, Slamon D, Koeffler HP. Abstract A96: Breast tumor subtypes and survival outcomes in African American and Latina patients in South Los Angeles Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A96 |
0.361 |
|
| 2009 |
Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research : Bcr. 11: R77. PMID 19874578 DOI: 10.1186/Bcr2419 |
0.318 |
|
| 2009 |
Slamon DJ, Press MF. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers. Journal of the National Cancer Institute. 101: 615-8. PMID 19401550 DOI: 10.1093/jnci/djp092 |
0.319 |
|
| 2009 |
Konecny GE, Manivong K, Guorong E, Glas R, Dering J, Anderson L, Ginther C, Velculescu V, Calzone F, Slamon DJ. Abstract B232: Preclinical evaluation of AMG479 a fully human insulin‐like growth factor receptor‐1 (IGFR1) antibody in ovarian cancer cells Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B232 |
0.426 |
|
| 2008 |
Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang S, Slamon DJ, Podratz KC. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. British Journal of Cancer. 98: 1076-1084. PMID 18334972 DOI: 10.1038/Sj.Bjc.6604278 |
0.461 |
|
| 2008 |
Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, Vadgama JV. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Research : Bcr. 10: R3. PMID 18184439 DOI: 10.1186/bcr1844 |
0.332 |
|
| 2007 |
Milstein M, Mooser CK, Hu H, Fejzo M, Slamon D, Goodglick L, Dry S, Colicelli J. RIN1 is a breast tumor suppressor gene. Cancer Research. 67: 11510-6. PMID 18089779 DOI: 10.1158/0008-5472.Can-07-1147 |
0.346 |
|
| 2007 |
Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment. 105: 319-26. PMID 17268817 DOI: 10.1007/s10549-006-9463-x |
0.382 |
|
| 2006 |
Slamon DJ, Romond EH, Perez EA. Advances in adjuvant therapy for breast cancer. Clinical Advances in Hematology & Oncology : H&O. 4: suppl 1, 4-9; discus. PMID 16736568 |
0.325 |
|
| 2006 |
Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Research. 66: 1630-9. PMID 16452222 DOI: 10.1158/0008-5472.CAN-05-1182 |
0.375 |
|
| 2006 |
Pietras RJ, Marquez DC, Chen H, Sliwkowski MX, Slamon DJ. Improved antitumor therapy by dual targeting of estrogen and growth factor receptor signaling in human breast cancer cells Journal of Clinical Oncology. 24: 637-637. DOI: 10.1200/Jco.2006.24.18_Suppl.637 |
0.4 |
|
| 2005 |
Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ, Slamon DJ. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Research : Bcr. 7: R1058-79. PMID 16457687 DOI: 10.1186/Bcr1343 |
0.422 |
|
| 2005 |
Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 16: 1772-7. PMID 16150805 DOI: 10.1093/Annonc/Mdi371 |
0.448 |
|
| 2005 |
Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Research : Bcr. 7: R436-43. PMID 15987448 DOI: 10.1186/bcr1020 |
0.31 |
|
| 2005 |
Wilson C, Dering J, Bernardo G, Rong H, Ginther C, Ferdman R, Cook A, Finn R, Slamon D. Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell lines Breast Cancer Research. 7: 1-1. DOI: 10.1186/Bcr1155 |
0.416 |
|
| 2004 |
Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, ... Slamon DJ, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer Journal of the National Cancer Institute. 96: 759-769. PMID 15150304 DOI: 10.1093/JNCI/DJH133 |
0.315 |
|
| 2004 |
Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. Journal of the National Cancer Institute. 96: 739-49. PMID 15150302 |
0.341 |
|
| 2003 |
Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. Journal of the National Cancer Institute. 95: 142-53. PMID 12529347 |
0.313 |
|
| 2002 |
Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 1: 117-23. PMID 12086869 DOI: 10.1016/s1535-6108(02)00039-9 |
0.308 |
|
| 2001 |
Konecny G, Fritz M, Untch M, Lebeau A, Felber M, Lude S, Beryt M, Hepp H, Slamon D, Pegram M. HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Research and Treatment. 69: 53-63. PMID 11759828 DOI: 10.1023/A:1012226006395 |
0.41 |
|
| 2001 |
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 61: 37-42. PMID 11694786 DOI: 10.1159/000055400 |
0.381 |
|
| 2001 |
Konecny G, Untch M, Slamon D, Beryt M, Kahlert S, Felber M, Langer E, Lude S, Hepp H, Pegram M. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples. Breast Cancer Research and Treatment. 67: 223-33. PMID 11561768 DOI: 10.1023/A:1017980411398 |
0.445 |
|
| 2001 |
Aguilar Z, Slamon DJ. The Transmembrane Heregulin Precursor Is Functionally Active Journal of Biological Chemistry. 276: 44099-44107. PMID 11495899 DOI: 10.1074/Jbc.M103442200 |
0.369 |
|
| 2001 |
Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Seminars in Oncology. 28: 13-9. PMID 11301370 DOI: 10.1016/S0093-7754(01)90188-5 |
0.451 |
|
| 2001 |
Nabholtz J, Slamon D. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Seminars in Oncology. 28: 1-12. PMID 11301369 DOI: 10.1016/S0093-7754(01)90187-3 |
0.438 |
|
| 2001 |
Lackey DB, Groziak MP, Sergeeva M, Beryt M, Boyer C, Stroud RM, Sayre P, Park JW, Johnston P, Slamon D, Shepard HM, Pegram M. Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochemical Pharmacology. 61: 179-89. PMID 11163332 DOI: 10.1016/S0006-2952(00)00542-6 |
0.355 |
|
| 2001 |
Nabholtz J-, Pienkowski T, Nothfelt D, Eiermann W, Quan E, Fumoleau P, Patel R, Crown J, Toppmeyer D, Slamon D. Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene European Journal of Cancer. 37. DOI: 10.1016/S0959-8049(01)81187-4 |
0.42 |
|
| 2001 |
Osoba D, Slamon D, Burchmore M, Murphy M. Health-related quality of life (HRQL) in women with HER2-positive metastatic breast cancer: effect of treatment with trastuzumab (Herceptin) plus chemotherapy versus chemotherapy alone European Journal of Cancer. 37. DOI: 10.1016/S0959-8049(01)81183-7 |
0.373 |
|
| 2001 |
Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. European Journal of Cancer. 37: 25-29. DOI: 10.1016/S0959-8049(00)00405-6 |
0.322 |
|
| 2000 |
Slamon D. Herceptin: increasing survival in metastatic breast cancer. European Journal of Oncology Nursing. 4: 24-29. PMID 12849614 DOI: 10.1054/Ejon.2000.0070 |
0.463 |
|
| 2000 |
Pauletti G, Dandekar S, Rong HM, Ramos L, Peng HJ, Seshadri R, Slamon DJ. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry Journal of Clinical Oncology. 18: 3651-3664. PMID 11054438 DOI: 10.1200/Jco.2000.18.21.3651 |
0.407 |
|
| 2000 |
Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treatment and Research. 103: 57-75. PMID 10948442 DOI: 10.1007/978-1-4757-3147-7_4 |
0.405 |
|
| 2000 |
Slamon D. Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results. Breast Cancer Research. 2: 1-1. DOI: 10.1186/Bcr134 |
0.39 |
|
| 2000 |
Paquette RL, Dergham ST, Karpf E, Wang H, Slamon DJ, Souza L, Glaspy JA. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood. 96: 2385-2390. DOI: 10.1182/Blood.V96.7.2385.H8002385_2385_2390 |
0.347 |
|
| 1999 |
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 2639-48. PMID 10561337 DOI: 10.1200/Jco.1999.17.9.2639 |
0.435 |
|
| 1999 |
Lopez AM, Pegram MD, Slamon DJ, Landaw EM. A model-based approach for assessing in vivo combination therapy interactions Proceedings of the National Academy of Sciences of the United States of America. 96: 13023-13028. PMID 10557266 DOI: 10.1073/Pnas.96.23.13023 |
0.343 |
|
| 1999 |
Oh JJ, Grosshans DR, Wong SG, Slamon DJ. Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells Nucleic Acids Research. 27: 4008-4017. PMID 10497265 DOI: 10.1093/Nar/27.20.4008 |
0.447 |
|
| 1999 |
Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 18: 2241-51. PMID 10327070 DOI: 10.1038/Sj.Onc.1202526 |
0.393 |
|
| 1999 |
Wilson CA, Ramos L, Villaseñor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nature Genetics. 21: 236-40. PMID 9988281 DOI: 10.1038/6029 |
0.43 |
|
| 1999 |
Slamon D, Leyland-Jones B, Shak S. Herceptin (R) improves time to progression following chemotherapy in women with metastatic breast cancer European Journal of Cancer. 35. DOI: 10.1016/S0959-8049(99)81677-3 |
0.383 |
|
| 1998 |
Pegram MD, Pauletti G, Slamon DJ. Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy Breast Cancer Research and Treatment. 52: 65-77. PMID 10066073 DOI: 10.1023/A:1006111117877 |
0.439 |
|
| 1998 |
Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 17: 2235-2249. PMID 9811454 DOI: 10.1038/Sj.Onc.1202132 |
0.379 |
|
| 1998 |
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2659-71. PMID 9704716 DOI: 10.1200/Jco.1998.16.8.2659 |
0.422 |
|
| 1998 |
Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. The Embo Journal. 17: 3052-65. PMID 9606188 DOI: 10.1093/Emboj/17.11.3052 |
0.394 |
|
| 1998 |
Landgraf R, Pegram M, Slamon DJ, Eisenberg D. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1. Biochemistry. 37: 3220-8. PMID 9485477 DOI: 10.1021/Bi972326Z |
0.3 |
|
| 1997 |
Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 15: 537-547. PMID 9247307 DOI: 10.1038/Sj.Onc.1201222 |
0.423 |
|
| 1997 |
Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese DM, Slamon DJ, Calzone FJ. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene. 14: 1-16. PMID 9010228 DOI: 10.1038/Sj.Onc.1200924 |
0.402 |
|
| 1997 |
Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells (Dayton, Ohio). 15: 1-8. PMID 9007217 DOI: 10.1002/Stem.150001 |
0.416 |
|
| 1996 |
Li B, Ouyang B, Pan H, Reissmann PT, Slamon DJ, Arceci R, Lu L, Dai W. Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. The Journal of Biological Chemistry. 271: 19402-8. PMID 8702627 DOI: 10.1074/Jbc.271.32.19402 |
0.351 |
|
| 1994 |
Strohmeyer TG, Slamon DJ. Proto-oncogenes and tumor suppressor genes in human urological malignancies. The Journal of Urology. 151: 1479-1497. PMID 8189554 DOI: 10.1016/S0022-5347(17)35284-9 |
0.306 |
|
| 1994 |
Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar A, Minna J. p53 Immunostaining Positivity Is Associated With Reduced Survival and Is Imperfectly Correlated With Gene Mutations in Resected Non-small Cell Lung Cancer: A Preliminary Report of LCSG 871 Chest. 106. DOI: 10.1378/Chest.106.6_Supplement.377S |
0.345 |
|
| 1994 |
Levin WJ, Casey G, Ramos JC, Arboleda MJ, Reissmann PT, Slamon DJ. Tumor Suppressor and Immediate Early Transcription Factor Genes in Non-small Cell Lung Cancer Chest. 106. DOI: 10.1378/Chest.106.6_Supplement.372S |
0.379 |
|
| 1991 |
Giovanella BC, Vardeman DM, Williams LJ, Taylor DJ, de Ipolyi PD, Greeff PJ, Stehlin JS, Ullrich A, Cailleau R, Slamon DJ. Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. International Journal of Cancer. Journal International Du Cancer. 47: 66-71. PMID 1985881 DOI: 10.1002/Ijc.2910470113 |
0.401 |
|
| 1991 |
Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R, Slamon D. Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proceedings of the National Academy of Sciences of the United States of America. 88: 6662-6. PMID 1862090 DOI: 10.1073/Pnas.88.15.6662 |
0.394 |
|
| 1991 |
Park JW, Stagg R, Lewis GD, Carter P, Maneval D, Slamon DJ, Jaffe H, Shepard HM. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treatment and Research. 61: 193-211. PMID 1360232 DOI: 10.1007/978-1-4615-3500-3_10 |
0.391 |
|
| 1990 |
Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon D, Lippman ME. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science (New York, N.Y.). 249: 1552-5. PMID 2218496 DOI: 10.1126/Science.2218496 |
0.37 |
|
| 1990 |
Slamon DJ. Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Investigation. 8: 253-254. PMID 1976032 DOI: 10.3109/07357909009017573 |
0.449 |
|
| 1990 |
Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. International Journal of Cancer. 45: 457-461. PMID 1968437 DOI: 10.1002/Ijc.2910450314 |
0.416 |
|
| 1989 |
Slamon DJ, Godolphin W, Ullrich A, Press MF. Studies of the HER-2/neu Proto-Oncogene in Human Breast Cancer Cancer Genetics and Cytogenetics. 41: 219. DOI: 10.1016/0165-4608(89)90255-0 |
0.421 |
|
| 1988 |
Slamon DJ, Clark GM. In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors? Science. 240: 1796-1798. PMID 17842433 DOI: 10.1126/Science.240.4860.1796 |
0.363 |
|
| 1988 |
Norman JT, Bohman RE, Fischmann G, Bowen JW, McDonough A, Slamon D, Fine LG. Patterns of mRNA expression during early cell growth differ in kidney epithelial cells destined to undergo compensatory hypertrophy versus regenerative hyperplasia. Proceedings of the National Academy of Sciences of the United States of America. 85: 6768-72. PMID 3413124 DOI: 10.1073/Pnas.85.18.6768 |
0.31 |
|
| 1988 |
Slamon D, Clark G. Amplification of c-erbB-2 and aggressive human breast tumors? Science. 240: 1795-1798. PMID 3289120 DOI: 10.1126/Science.3289120 |
0.363 |
|
| 1987 |
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. 235: 177-182. PMID 3798106 DOI: 10.1126/Science.3798106 |
0.457 |
|
| 1987 |
Slamon DJ. Proto-oncogenes and human cancers. The New England Journal of Medicine. 317: 955-957. PMID 3627214 DOI: 10.1056/Nejm198710083171509 |
0.339 |
|
| 1987 |
McGuire WL, Johnson BE, Seeger RC, Slamon DJ. Oncogenes in clinical cancer--a panel discussion. Breast Cancer Research and Treatment. 10: 217-227. PMID 2833962 DOI: 10.1007/Bf01805759 |
0.346 |
|
| 1986 |
Shah NP, Wachsman W, Cann AJ, Souza L, Slamon DJ, Chen ISY. Comparison of the trans-activation capabilities of the human T-cell leukemia virus type I and II chi proteins. Molecular and Cellular Biology. 6: 3626-3631. PMID 3025604 DOI: 10.1128/Mcb.6.11.3626 |
0.306 |
|
| 1986 |
Slamon DJ, Boone TC, Murdock DC, Keith DE, Press MF, Larson RA, Souza LM. Studies of the human c-myb gene and its product in human acute leukemias. Science. 233: 347-351. PMID 3014652 DOI: 10.1126/Science.3014652 |
0.311 |
|
| 1986 |
Slamon DJ, Boone TC, Seeger RC, Keith DE, Chazin V, Lee HC, Souza LM. Identification and characterization of the protein encoded by the human N-myc oncogene. Science. 232: 768-772. PMID 3008339 DOI: 10.1126/Science.3008339 |
0.321 |
|
| 1984 |
Slamon DJ, deKernion JB, Verma IM, Cline MJ. Expression of cellular oncogenes in human malignancies. Science (New York, N.Y.). 224: 256-62. PMID 6538699 DOI: 10.1126/Science.6538699 |
0.315 |
|
| 1984 |
Cline MJ, Slamon DJ, Lipsick JS. Oncogenes: implications for the diagnosis and treatment of cancer. Annals of Internal Medicine. 101: 223-33. PMID 6331242 DOI: 10.7326/0003-4819-101-2-223 |
0.394 |
|
| Show low-probability matches. |